ScholarIQanswers from OpenAlex & ORCID
Bilal Piperdi
ResearcherPublications, citations & collaboration network
Bilal Piperdi is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Bilal Piperdi have?
ScholarIQindexed works
Bilal Piperdi has 170 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Bilal Piperdi have?
ScholarIQcitation count
Bilal Piperdi has 17,107 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Bilal Piperdi?
ScholarIQh-index
Bilal Piperdi has an h-index of 42 in OpenAlex.
What is the i10-index of Bilal Piperdi?
ScholarIQi10-index
Bilal Piperdi has an i10-index of 89 in OpenAlex.
What is the ORCID of Bilal Piperdi?
ScholarIQorcid
The ORCID for Bilal Piperdi is on the source record.
What is the OpenAlex record for Bilal Piperdi?
ScholarIQopenalex
The OpenAlex for Bilal Piperdi is on the source record.
What are the most-cited papers on Bilal Piperdi?
ScholarIQmost cited works
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
Luis Paz‐Ares, Alexander Luft, David Vicente, Ali Tafreshi, Mahmut Gümüş, Julien Mazières, Bárbara Hermes, Filiz Çay Şenler, Tibor Csőszi, Andrea Fülöp, Jerónimo Rafael Rodríguez‐Cid, Jonathan Wilson, Shunichi Sugawara, Terufumi Kato, Ki Hyeong Lee, Ying Cheng, Silvia Novello, Balázs Halmos, Xiaodong Li, Gregory M. Lubiniecki, Bilal Piperdi, Dariusz M. Kowalski
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407
Luis Paz‐Ares, David Vicente, Ali Tafreshi, Andrew Robinson, Héctor Soto Parrà, Julien Mazières, Bárbara Hermes, İrfan Çiçin, Balazs Medgyasszay, Jerónimo Rafael Rodríguez‐Cid, Isamu Okamoto, Sung-Sook Lee, Rodryg Ramlau, Vladimir Vladimirov, Ying Cheng, Xuan Deng, Ying Zhang, Tuba Öcek Baş, Bilal Piperdi, Balázs Halmos
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study
Michael Boyer, Mehmet Alı Nahıt Şendur, Delvys Rodríguez‐Abreu, Keunchil Park, Dae Ho Lee, İrfan Çiçin, Perran Fulden Yumuk, Francesco Orlandi, Ticiana Leal, Olivier Molinier, Nopadol Soparattanapaisarn, Adrian Langleben, Raffaele Califano, Balazs Medgyasszay, Te‐Chun Hsia, Gregory A. Otterson, Lu Xu, Bilal Piperdi, Ayman Samkari, Martin Reck, for the KEYNOTE-598 Investigators